Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.04
NYSE:VRX's Cash-to-Debt is ranked lower than
96% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NYSE:VRX: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:VRX' s Cash-to-Debt Range Over the Past 10 Years
Min: -1.06  Med: 0.19 Max: No Debt
Current: 0.04
-1.06
No Debt
Equity-to-Asset 0.13
NYSE:VRX's Equity-to-Asset is ranked lower than
96% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:VRX: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:VRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.46 Max: 0.85
Current: 0.13
0.07
0.85
Debt-to-Equity 5.10
NYSE:VRX's Debt-to-Equity is ranked lower than
99% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NYSE:VRX: 5.10 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:VRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.79 Max: 9.47
Current: 5.1
0.04
9.47
Debt-to-EBITDA 7.69
NYSE:VRX's Debt-to-EBITDA is ranked lower than
93% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NYSE:VRX: 7.69 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:VRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28  Med: 8.03 Max: 36
Current: 7.69
0.28
36
Interest Coverage 0.31
NYSE:VRX's Interest Coverage is ranked lower than
99.99% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. NYSE:VRX: 0.31 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:VRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.17  Med: 2.06 Max: 121.91
Current: 0.31
0.17
121.91
Piotroski F-Score: 5
Altman Z-Score: 0.30
Beneish M-Score: -2.83
WACC vs ROIC
6.18%
-1.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 6.50
NYSE:VRX's Operating Margin % is ranked lower than
76% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NYSE:VRX: 6.50 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:VRX' s Operating Margin % Range Over the Past 10 Years
Min: -9.32  Med: 13.49 Max: 24.38
Current: 6.5
-9.32
24.38
Net Margin % 14.51
NYSE:VRX's Net Margin % is ranked lower than
78% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NYSE:VRX: 14.51 )
Ranked among companies with meaningful Net Margin % only.
NYSE:VRX' s Net Margin % Range Over the Past 10 Years
Min: -24.9  Med: 1.89 Max: 26.4
Current: 14.51
-24.9
26.4
ROE % 31.91
NYSE:VRX's ROE % is ranked lower than
81% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NYSE:VRX: 31.91 )
Ranked among companies with meaningful ROE % only.
NYSE:VRX' s ROE % Range Over the Past 10 Years
Min: -52.21  Med: 0.33 Max: 31.91
Current: 31.91
-52.21
31.91
ROA % 3.04
NYSE:VRX's ROA % is ranked lower than
71% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NYSE:VRX: 3.04 )
Ranked among companies with meaningful ROA % only.
NYSE:VRX' s ROA % Range Over the Past 10 Years
Min: -5.13  Med: 0.3 Max: 13.02
Current: 3.04
-5.13
13.02
ROC (Joel Greenblatt) % 24.74
NYSE:VRX's ROC (Joel Greenblatt) % is ranked lower than
75% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NYSE:VRX: 24.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:VRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -69.94  Med: 64.52 Max: 144.06
Current: 24.74
-69.94
144.06
3-Year Revenue Growth Rate 24.80
NYSE:VRX's 3-Year Revenue Growth Rate is ranked higher than
89% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NYSE:VRX: 24.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:VRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.8  Med: 27.4 Max: 82.5
Current: 24.8
-10.8
82.5
3-Year EBITDA Growth Rate 19.30
NYSE:VRX's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NYSE:VRX: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:VRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35.7  Med: 19.3 Max: 113.3
Current: 19.3
-35.7
113.3
3-Year EPS without NRI Growth Rate 47.70
NYSE:VRX's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NYSE:VRX: 47.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:VRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 20.75 Max: 101
Current: 47.7
-37.1
101
GuruFocus has detected 2 Warning Signs with Valeant Pharmaceuticals International Inc NYSE:VRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:VRX's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

VRX Guru Trades in Q4 2016

Jim Simons 2,913,089 sh (+573.56%)
First Eagle Investment 613,800 sh (+61.14%)
Private Capital 478,125 sh (+37.64%)
Francis Chou 1,960,843 sh (+35.53%)
John Paulson 19,384,500 sh (+2.72%)
George Soros 500,000 sh (unchged)
Steven Cohen 1,320,000 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Chris Davis 7,000,303 sh (-4.95%)
Bill Ackman 18,114,432 sh (-16.10%)
Diamond Hill Capital 34,500 sh (-90.04%)
» More
Q1 2017

VRX Guru Trades in Q1 2017

Murray Stahl 26,485 sh (New)
Steven Cohen 359,000 sh (New)
Francis Chou 2,353,843 sh (+20.04%)
Jeff Ubben 17,997,224 sh (+20.03%)
Private Capital 481,390 sh (+0.68%)
John Paulson 19,384,500 sh (unchged)
Diamond Hill Capital 34,500 sh (unchged)
Bill Ackman Sold Out
Jim Simons Sold Out
First Eagle Investment 613,100 sh (-0.11%)
Chris Davis 3,917,812 sh (-44.03%)
» More
Q2 2017

VRX Guru Trades in Q2 2017

Robert Bruce 581,000 sh (New)
Ray Dalio 70,269 sh (New)
Jim Simons 2,402,589 sh (New)
Joel Greenblatt 823,046 sh (New)
Francis Chou 3,053,843 sh (+29.74%)
John Paulson 21,813,400 sh (+12.53%)
Diamond Hill Capital 34,500 sh (unchged)
George Soros 1,650,000 sh (unchged)
Jeff Ubben 17,997,224 sh (unchged)
Chris Davis Sold Out
Private Capital Sold Out
Murray Stahl 26,273 sh (-0.80%)
First Eagle Investment 551,300 sh (-10.08%)
Steven Cohen 50,000 sh (-86.07%)
» More
Q3 2017

VRX Guru Trades in Q3 2017

Lee Ainslie 276,490 sh (New)
Jim Simons 4,780,500 sh (+98.97%)
Jeff Ubben 18,010,027 sh (+0.07%)
Diamond Hill Capital 34,500 sh (unchged)
First Eagle Investment 551,300 sh (unchged)
Ray Dalio 70,269 sh (unchged)
Murray Stahl 26,273 sh (unchged)
George Soros 2,160,000 sh (unchged)
Francis Chou 3,053,843 sh (unchged)
Steven Cohen 3,500,000 sh (unchged)
Robert Bruce 581,000 sh (unchged)
Steven Cohen Sold Out
John Paulson 20,839,035 sh (-4.47%)
Joel Greenblatt 475,002 sh (-42.29%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-09-30 Reduce -4.47%0.23%$13.1 - $17.77 $ 15.573%20,839,035
Joel Greenblatt 2017-09-30 Reduce -42.29%0.08%$13.1 - $17.77 $ 15.573%475,002
John Paulson 2017-08-09 Reduce -4.47%0.21%Premium Member Access $15.64 $ 15.57-0%20,839,035
John Paulson 2017-06-30 Add 12.53%0.57%$8.51 - $17.31 $ 15.5730%21,813,400
Joel Greenblatt 2017-06-30 New Buy0.2%$8.51 - $17.31 $ 15.5730%823,046
Robert Bruce 2017-06-30 New Buy2.59%$8.51 - $17.31 $ 15.5730%581,000
First Eagle Investment 2017-06-30 Reduce -10.08%$8.51 - $17.31 $ 15.5731%551,300
Chris Davis 2017-06-30 Sold Out 0.19%$8.51 - $17.31 $ 15.5730%0
Private Capital 2017-06-30 Sold Out 0.82%$8.51 - $17.31 $ 15.5730%0
John Paulson 2017-06-14 Add 12.53%0.4%Premium Member Access $12.46 $ 15.5725%21,813,400
Chris Davis 2017-03-31 Reduce -44.03%0.2%$10.64 - $16.86 $ 15.5713%3,917,812
First Eagle Investment 2017-03-31 Reduce -0.11%$10.64 - $16.86 $ 15.5713%613,100
Private Capital 2017-03-31 Add 0.68%0.01%$10.64 - $16.86 $ 15.5713%481,390
Bill Ackman 2017-03-31 Sold Out 4.45%$10.64 - $16.86 $ 15.5713%0
Bill Ackman 2017-03-13 Sold Out 4.45%Premium Member Access $12.11 $ 15.5729%0
John Paulson 2016-12-31 Add 2.72%0.1%$13.6 - $24.59 $ 15.57-15%19,384,500
Bill Ackman 2016-12-31 Reduce -16.10%1.58%$13.6 - $24.59 $ 15.57-15%18,114,432
Chris Davis 2016-12-31 Reduce -4.95%0.04%$13.6 - $24.59 $ 15.57-15%7,000,303
First Eagle Investment 2016-12-31 Add 61.14%0.01%$13.6 - $24.59 $ 15.57-15%613,800
Private Capital 2016-12-31 Add 37.64%0.29%$13.6 - $24.59 $ 15.57-15%478,125
Ruane Cunniff 2016-12-31 Sold Out 0.06%$13.6 - $24.59 $ 15.57-15%0
Bill Ackman 2016-12-12 Reduce -16.10%0.94%Premium Member Access $14.68 $ 15.576%18,114,432
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:SZSE:002001, SZSE:300142, NAS:AKRX, SZSE:000623, SZSE:300558, SHSE:600521, NYSE:TARO, NAS:OPK, SZSE:000999, SHSE:600079, TSE:4530, HKSE:00867, BUD:RICHTER, LSE:HIK, NSE:DIVISLAB, SHSE:600511, SZSE:000513, TSE:4516, NSE:ALKEM, HKSE:00460 » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Headquarter Location:Canada
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia.

Ratios

vs
industry
vs
history
PE Ratio 4.04
VRX's PE Ratio is ranked lower than
99.99% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. VRX: 4.04 )
Ranked among companies with meaningful PE Ratio only.
VRX' s PE Ratio Range Over the Past 10 Years
Min: 3.04  Med: 18.67 Max: 710.87
Current: 4.04
3.04
710.87
Forward PE Ratio 3.65
VRX's Forward PE Ratio is ranked higher than
96% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. VRX: 3.65 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 4.04
VRX's PE Ratio without NRI is ranked lower than
99.99% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. VRX: 4.04 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.04  Med: 18.67 Max: 710.87
Current: 4.04
3.04
710.87
Price-to-Owner-Earnings 3.31
VRX's Price-to-Owner-Earnings is ranked higher than
85% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. VRX: 3.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.5  Med: 21.92 Max: 805.48
Current: 3.31
2.5
805.48
PB Ratio 1.03
VRX's PB Ratio is ranked higher than
85% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. VRX: 1.03 )
Ranked among companies with meaningful PB Ratio only.
VRX' s PB Ratio Range Over the Past 10 Years
Min: 0.76  Med: 2.58 Max: 14.44
Current: 1.03
0.76
14.44
PS Ratio 0.58
VRX's PS Ratio is ranked higher than
92% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. VRX: 0.58 )
Ranked among companies with meaningful PS Ratio only.
VRX' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 3.61 Max: 10.51
Current: 0.58
0.32
10.51
Price-to-Free-Cash-Flow 2.74
VRX's Price-to-Free-Cash-Flow is ranked higher than
97% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. VRX: 2.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.44  Med: 13.4 Max: 276.26
Current: 2.74
1.44
276.26
Price-to-Operating-Cash-Flow 2.31
VRX's Price-to-Operating-Cash-Flow is ranked higher than
98% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. VRX: 2.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.22  Med: 10.85 Max: 48.3
Current: 2.31
1.22
48.3
EV-to-EBIT 52.49
VRX's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. VRX: 52.49 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1211.6  Med: 12.8 Max: 379.5
Current: 52.49
-1211.6
379.5
EV-to-EBITDA 9.00
VRX's EV-to-EBITDA is ranked higher than
56% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. VRX: 9.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 16.2 Max: 147.6
Current: 9
-31
147.6
EV-to-Revenue 3.33
VRX's EV-to-Revenue is ranked lower than
54% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. VRX: 3.33 )
Ranked among companies with meaningful EV-to-Revenue only.
VRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 5.9 Max: 14
Current: 3.33
1.3
14
PEG Ratio 0.10
VRX's PEG Ratio is ranked lower than
99.99% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. VRX: 0.10 )
Ranked among companies with meaningful PEG Ratio only.
VRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.1  Med: 1.49 Max: 262.78
Current: 0.1
0.1
262.78
Current Ratio 1.26
VRX's Current Ratio is ranked lower than
78% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. VRX: 1.26 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.54 Max: 9.68
Current: 1.26
0.72
9.68
Quick Ratio 1.03
VRX's Quick Ratio is ranked lower than
72% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. VRX: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.2 Max: 9.3
Current: 1.03
0.59
9.3
Days Inventory 160.31
VRX's Days Inventory is ranked lower than
73% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. VRX: 160.31 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.84  Med: 140.69 Max: 169.11
Current: 160.31
115.84
169.11
Days Sales Outstanding 85.22
VRX's Days Sales Outstanding is ranked lower than
58% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. VRX: 85.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 82.81 Max: 106.05
Current: 85.22
43.41
106.05
Days Payable 54.40
VRX's Days Payable is ranked lower than
64% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. VRX: 54.40 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 45.29  Med: 79.15 Max: 120.5
Current: 54.4
45.29
120.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
VRX's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. VRX: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.7  Med: -3 Max: 14
Current: -1.5
-34.7
14

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.22
VRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
98% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. VRX: 0.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.18  Med: 1.74 Max: 11.22
Current: 0.22
0.18
11.22
Price-to-Median-PS-Value 0.16
VRX's Price-to-Median-PS-Value is ranked higher than
98% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. VRX: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.55 Max: 5.99
Current: 0.16
0.11
5.99
Price-to-Peter-Lynch-Fair-Value 0.16
VRX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. VRX: 0.16 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
VRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.14  Med: 2.29 Max: 117.96
Current: 0.16
0.14
117.96
Earnings Yield (Greenblatt) % 1.90
VRX's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. VRX: 1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.8  Med: 1.4 Max: 22.8
Current: 1.9
-11.8
22.8
Forward Rate of Return (Yacktman) % 58.88
VRX's Forward Rate of Return (Yacktman) % is ranked higher than
97% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. VRX: 58.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 20.9 Max: 97.3
Current: 58.88
2.5
97.3

More Statistics

Revenue (TTM) (Mil) $8,964.00
EPS (TTM) $ 3.90
Beta-1.06
Short Percentage of Float13.79%
52-Week Range $8.31 - 18.65
Shares Outstanding (Mil)348.59

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 8,693 8,469 8,852 9,048
EPS ($) 3.91 3.90 4.65 5.25
EPS without NRI ($) 3.91 3.90 4.65 5.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}